BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26683226)

  • 1. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
    Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
    Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of metadherin inhibits cell proliferation and migration in colorectal cancer.
    Li JW; Huang CZ; Li JH; Yuan JH; Chen QH; Zhang WF; Xu ZS; Liu YP; Li Y; Zhan MX; Lu LG
    Oncol Rep; 2018 Oct; 40(4):2215-2223. PubMed ID: 30015962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
    De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
    Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
    Cagnetta A; Cea M; Calimeri T; Acharya C; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Zhong MY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2013 Aug; 122(7):1243-55. PubMed ID: 23823317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
    Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
    Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lobaplatin inhibits breast cancer progression, cell proliferation while it induces cell apoptosis by downregulating MTDH expression.
    Tian W; Hao S; Gao B; Jiang Y; Zhang X; Zhang S; Guo L; Zhao J; Zhang G; Chen Y; Li Z; Luo D
    Drug Des Devel Ther; 2018; 12():3563-3571. PubMed ID: 30464390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma.
    Matsuda T; Takeuchi H; Matsuda S; Hiraiwa K; Miyasho T; Okamoto M; Kawasako K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S356-64. PubMed ID: 24566863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma.
    Dong R; Liu X; Zhang Q; Jiang Z; Li Y; Wei Y; Li Y; Yang Q; Liu J; Wei JJ; Shao C; Liu Z; Kong B
    Oncotarget; 2014 Nov; 5(21):10816-29. PubMed ID: 25333261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
    Longo J; Smirnov P; Li Z; Branchard E; van Leeuwen JE; Licht JD; Haibe-Kains B; Andrews DW; Keats JJ; Pugh TJ; Trudel S; Penn LZ
    Leukemia; 2021 Mar; 35(3):796-808. PubMed ID: 32665698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
    Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
    Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
    Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
    Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells.
    Mizuno S; Hanamura I; Ota A; Karnan S; Narita T; Ri M; Mizutani M; Goto M; Gotou M; Tsunekawa N; Shikami M; Iida S; Hosokawa Y; Miwa H; Ueda R; Nitta M; Takami A
    Int J Hematol; 2015 Nov; 102(5):569-78. PubMed ID: 26341959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation.
    Gollavilli PN; Kanugula AK; Koyyada R; Karnewar S; Neeli PK; Kotamraju S
    FEBS J; 2015 Oct; 282(20):3971-85. PubMed ID: 26236947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.
    Min DJ; Ezponda T; Kim MK; Will CM; Martinez-Garcia E; Popovic R; Basrur V; Elenitoba-Johnson KS; Licht JD
    Leukemia; 2013 Mar; 27(3):686-94. PubMed ID: 22972034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metadherin regulates actin cytoskeletal remodeling and enhances human gastric cancer metastasis via epithelial-mesenchymal transition.
    Du Y; Jiang B; Song S; Pei G; Ni X; Wu J; Wang S; Wang Z; Yu J
    Int J Oncol; 2017 Jul; 51(1):63-74. PubMed ID: 28534938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
    Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
    Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
    Zhang XD; Baladandayuthapani V; Lin H; Mulligan G; Li B; Esseltine DW; Qi L; Xu J; Hunziker W; Barlogie B; Usmani SZ; Zhang Q; Crowley J; Hoering A; Shah JJ; Weber DM; Manasanch EE; Thomas SK; Li BZ; Wang HH; Zhang J; Kuiatse I; Tang JL; Wang H; He J; Yang J; Milan E; Cenci S; Ma WC; Wang ZQ; Davis RE; Yang L; Orlowski RZ
    Cancer Cell; 2016 May; 29(5):639-652. PubMed ID: 27132469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
    Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
    Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metadherin contributes to the pathogenesis of diffuse large B-cell lymphoma.
    Ge X; Lv X; Feng L; Liu X; Gao J; Chen N; Wang X
    PLoS One; 2012; 7(6):e39449. PubMed ID: 22768080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.